In a cohort of persons with chronic coronary syndrome, we investigated associations of blood-based biomarkers of neurodegenerative diseases with cognitive scores and mild cognitive impairment (MCI) after ten years. Biomarker levels were measured in baseline samples of serum (glial fibrillary acid protein, neurofilament light chain (NfL), phosphorylated tau181; n = 363) or plasma (amyloid-β42/40-ratio, total-tau; n = 232). Cognitive scores and MCI were measured at ten-year follow-up using the Cognitive Telephone Screening Instrument. At follow-up, 14.7% had MCI. The amyloid-β42/40-ratio was predictive of cognitive scores, while NfL was associated with increased risk of MCI, suggesting that these biomarkers might be utilized for risk stratification.
Keywords: Alzheimer's disease; amyloid-beta ratio; biomarkers of neurodegenerative diseases; chronic coronary syndrome; cognition; epidemiology; mild cognitive impairment; neurofilament light chain.